STENOCARE initiates guidance: 15-20mDKK in annual revenue run rate by end of 2022
STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER: STENO This information is information that STENOCARE A/S is obliged to publish in accordance with the EU Market Abuse Regulation. The information was provided by the contact person below for publication on March 10, 2022. STENOCARE A/S (“STENOCARE”) has successfully reached two important license milestones during Q1 2022: The first medical cannabis oil products have been approved for Denmark and three new medical cannabis oil products have been approved for the UK. This enables the company to realize sales of